• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Aerovate Therapeutics Inc.

    5/16/24 4:20:24 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTE alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001185035
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    AEROVATE THERAPEUTICS, INC.
    SEC File Number
    001-40544
    Address of Issuer
    930 Winter Street, Suite M-500
    Waltham
    MASSACHUSETTS
    02451
    Phone
    (617) 443-2400
    Name of Person for Whose Account the Securities are To Be Sold
    TIMOTHY NOYES
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    10000215755.002880833405/16/2024
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    COMMON05/16/2024Stock Option ExerciseISSUERCheckbox not checked1000005/16/2024Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    TIMOTHY NOYES
    930 Winter Street, Suite M-500
    Waltham � MA � 02451
    Common05/01/2024135727017.87
    TIMOTHY NOYES
    930 Winter Street, Suite M-500
    Waltham � MA � 02451
    Common05/01/202410000203927.00
    TIMOTHY NOYES
    930 Winter Street, Suite M-500
    Waltham � MA � 02451
    Common04/16/202410000246970.00
    TIMOTHY NOYES
    930 Winter Street, Suite M-500
    Waltham � MA � 02451
    Common04/01/202410000300033.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/16/2024
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    11/27/2023

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Timothy Paul Noyes

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $AVTE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTE

    DatePrice TargetRatingAnalyst
    6/18/2024$27.00 → $2.00Outperform → In-line
    Evercore ISI
    6/18/2024Buy → Hold
    TD Cowen
    6/18/2024$35.00 → $2.00Overweight → Equal Weight
    Wells Fargo
    6/17/2024Buy → Neutral
    Guggenheim
    6/17/2024Buy → Neutral
    BTIG Research
    6/17/2024$41.00 → $3.00Outperform → Neutral
    Wedbush
    3/25/2024$21.00 → $65.00Buy
    Jefferies
    12/8/2023$35.00Equal Weight
    Wells Fargo
    More analyst ratings

    $AVTE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Fairmount Funds Management Llc

    4 - Jade Biosciences, Inc. (0001798749) (Issuer)

    5/1/25 6:16:57 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lavelle Erin

    4 - Jade Biosciences, Inc. (0001798749) (Issuer)

    5/1/25 6:15:30 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Klein Lawrence Otto

    4 - Jade Biosciences, Inc. (0001798749) (Issuer)

    5/1/25 6:10:20 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aerovate Therapeutics downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Aerovate Therapeutics from Outperform to In-line and set a new price target of $2.00 from $27.00 previously

    6/18/24 7:32:31 AM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aerovate Therapeutics downgraded by TD Cowen

    TD Cowen downgraded Aerovate Therapeutics from Buy to Hold

    6/18/24 7:23:55 AM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aerovate Therapeutics downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Aerovate Therapeutics from Overweight to Equal Weight and set a new price target of $2.00 from $35.00 previously

    6/18/24 7:22:03 AM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTE
    SEC Filings

    View All

    $AVTE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AVTE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Aerovate Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Material Modification to Rights of Security Holders, Regulation FD Disclosure

    8-K - Jade Biosciences, Inc. (0001798749) (Filer)

    5/1/25 4:22:23 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Aerovate Therapeutics Inc.

    SCHEDULE 13D/A - Jade Biosciences, Inc. (0001798749) (Subject)

    4/30/25 4:51:40 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aerovate Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Aerovate Therapeutics, Inc. (0001798749) (Filer)

    4/29/25 4:05:20 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals

    —Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger. The proposals were voted upon at Aerovate's special meeting of stockholders held on April 16, 2025 (the "Special Meeting"), including a reverse stock split of Aerovate's common stock to be effected at the discretion of the Board of Directors (the "Board") within the parameters approved by Aerovate's stockholders. On April 18, 2025, the Board approved a fi

    4/21/25 8:00:00 AM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

    Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share WALTHAM, Mass., April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement"). The Cash Dividend will be an aggregate of $69.6 million, or an estimated $2.40 per share, payable in cash to the stockholders of record as of April 25, 2025. The estimated per share dividend is based on 28,985,019 shares of

    4/9/25 4:05:00 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

    Cash dividend expected to be in the range of $67.6 – 69.6 million WALTHAM, Mass., April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to declare a cash dividend to the pre-Merger Aerovate stockholders (the "Cash Dividend") in the range of $67.6 – 69.6 million in the aggregate. This expected dividend range is based on Aerovate's estimated net cash immediately prior to the closing of the Merger (the "Closing"). As of April 4, 2025, 28,985,019 shares of Aerovate's common stock are outstanding. Official declaration of the Cash D

    4/7/25 8:30:00 AM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $1,549,944 worth of shares (928,110 units at $1.67) (SEC Form 4)

    4 - Aerovate Therapeutics, Inc. (0001798749) (Issuer)

    6/20/24 5:56:07 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTE
    Financials

    Live finance-specific insights

    View All

    Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals

    —Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger. The proposals were voted upon at Aerovate's special meeting of stockholders held on April 16, 2025 (the "Special Meeting"), including a reverse stock split of Aerovate's common stock to be effected at the discretion of the Board of Directors (the "Board") within the parameters approved by Aerovate's stockholders. On April 18, 2025, the Board approved a fi

    4/21/25 8:00:00 AM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

    Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share WALTHAM, Mass., April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement"). The Cash Dividend will be an aggregate of $69.6 million, or an estimated $2.40 per share, payable in cash to the stockholders of record as of April 25, 2025. The estimated per share dividend is based on 28,985,019 shares of

    4/9/25 4:05:00 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

    Cash dividend expected to be in the range of $67.6 – 69.6 million WALTHAM, Mass., April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to declare a cash dividend to the pre-Merger Aerovate stockholders (the "Cash Dividend") in the range of $67.6 – 69.6 million in the aggregate. This expected dividend range is based on Aerovate's estimated net cash immediately prior to the closing of the Merger (the "Closing"). As of April 4, 2025, 28,985,019 shares of Aerovate's common stock are outstanding. Official declaration of the Cash D

    4/7/25 8:30:00 AM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTE
    Leadership Updates

    Live Leadership Updates

    View All

    Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

    WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board. Mr. Dable succeeds Mark Iwicki, who will continue to serve on the Board. "We are pleased to have Habib take on the role of Chair of the Board," said Tim Noyes, Chief Executive Officer of Aerovate Therapeutics. "With the Phase 2b data readout from our global IMPAHCT trial of AV-101 in PAH coming in June and our Phase 3 trial already well underway,

    3/6/24 8:00:00 AM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors

    WALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Habib Dable as a member of Aerovate's Board of Directors. Mr. Dable is the former President and Chief Executive Officer of Acceleron Pharma Inc. and brings nearly three decades of experience working with emerging biotech and big pharma companies. "We are excited to welcome Habib to Aerovate's Board of Directors. Habib's deep experience in leading both big pharma and emerging biotech companies will be incredibly

    7/11/23 5:00:00 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

    WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as a member of Aerovate's Board of Directors. With over 40 years of working in the industry, Mr. Santel brings to Aerovate extensive experience in building successful pharmaceutical companies. "We are excited to welcome Don to Aerovate's Board of Directors. Don's proven track record of leading and building biopharmaceutical companies from the ground up and taking them through extensive periods of g

    1/23/23 8:00:00 AM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTE
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Led to the Purchase at Aerovate Therapeutics Inc. on Jun 20?

    Recently, on June 20, 2024, a notable insider purchase was made at Aerovate Therapeutics Inc. Director Ra Capital Management, L.P. bought $1,549,944 worth of shares, acquiring 928,110 units at $1.67 per share as reported in the SEC Form 4. Insider transactions like these are closely watched by investors as they can provide valuable insights into the company's prospects. When analyzing insider transactions, it is essential to look for patterns and trends among multiple transactions to gauge the overall sentiment within the company. Several other SEC Form 4 filings were made around the same time, on June 7, 2024, by various insiders at Aerovate Therapeutics Inc. These included transactions by

    6/21/24 3:23:59 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aerovate Therapeutics Inc.

    SC 13G/A - Aerovate Therapeutics, Inc. (0001798749) (Subject)

    11/14/24 4:21:04 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Aerovate Therapeutics Inc.

    SC 13D/A - Aerovate Therapeutics, Inc. (0001798749) (Subject)

    6/20/24 6:00:09 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Aerovate Therapeutics Inc. (Amendment)

    SC 13D/A - Aerovate Therapeutics, Inc. (0001798749) (Subject)

    4/30/24 4:16:13 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care